A practical reference on lyophilisation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-18 and is reviewed periodically as new material appears.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
The two substrates of this enzyme are L-aspartic acid and oxygen. Its products are iminosuccinic acid and hydrogen peroxide. In Escherichia coli another enzyme, quinolinate synthase, takes the product with dihydroxyacetone phosphate to form quinolinic acid but simple hydrolysis gives oxaloacetic acid. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with oxygen as acceptor. The systematic name of this enzyme class is L-aspartate:oxygen oxidoreductase (deaminating). This enzyme is part of the pathway for alanine metabolism and nicotinamide adenine dinucleotide biosynthesis. It employs one cofactor, flavin adenine dinucleotide.
A chaotropic agent is a molecule in water solution that can disrupt the hydrogen bonding network between water molecules (i.e. exerts chaotropic activity). This has an effect on the stability of the native state of other molecules in the solution, mainly macromolecules (proteins, nucleic acids) by weakening the hydrophobic effect. For example, a chaotropic agent reduces the amount of order in the structure of a protein formed by water molecules, both in the bulk and the hydration shells around hydrophobic amino acids, and may cause its denaturation. Conversely, an antichaotropic agent (kosmotropic) is a molecule in an aqueous solution that will increase the hydrophobic effects within the solution. Antichaotropic salts such as ammonium sulphate can be used to precipitate substances from the impure mixture. This is used in protein purification processes, to remove undesired proteins from solution.
=== Structural convergence === Here is a list of examples in which unrelated proteins have similar tertiary structures but different functions. Whole protein structural convergence is not thought to occur but some convergence of pockets and secondary structural elements have been documented.
== History == The 75th Infantry was constituted on 10 July 1918 in the Regular Army as the 75th Infantry and assigned to the 13th Division. It was organized in August 1918 at Camp Lewis, Washington, from personnel of the 1st Infantry. The 75th Infantry was part of the "square" 13th Division's complement of four regiments including the 1st, 44th, 75th, and 76th Infantry Regiments. It was never sent overseas during World War I, and was relieved from the 13th Division and demobilized on 27 February 1919 at Camp Lewis. The 75th Infantry was reconstituted on 18 July 1941 in the Regular Army, but never activated. It was disbanded on 4 August 1952. The 75th was never authorized a coat of arms or distinctive unit insignia. The present day 75th Ranger Regiment shares a number but no lineage with this regiment.
Sources: en.wikipedia.org
== Medical uses == Topilutamide is used as a topical medication in the treatment of pattern hair loss in men and women. Topilutamide is approved for cosmetic use in Europe but has not received FDA approval nor approval by the EMA for the treatment of androgenetic alopecia. Finasteride and Minoxidil are currently the only treatments approved for the treatment of this condition.
=== Early detection === From May to August 1939 the LZ130 Graf Zeppelin II made flights along Britain's North Sea coast to investigate the 100-metre-high radio towers that were being erected from Portsmouth to Scapa Flow. LZ130 performed a series of radiometric tests and took photographs. German sources report the 12 m Chain Home signals were detected and suspected to be radar; however, the chief investigator was not able to prove his suspicions. Other sources are said to report different results. During the Battle of France, the Germans observed 12 m pulse signals on the western front without being able to recognize their origin and purpose. In mid-June 1940, the Deutsche Versuchsanstalt für Luftfahrt (DVL, German Aeronautic Research Institute) set up a special group under the direction of Professor von Handel and found out that the signals originated from the installations on the coast of the English Channel. Their suspicions were finally proven in the aftermath of the Battle of Dunkirk, when the British were forced to abandon a mobile gun-laying radar (GL Mk. I) station in Normandy. Wolfgang Martini's team of specialists was able to determine the operation of the system. GL was a rather crude system of limited effectiveness, and this led the Germans to have a dim view of British radar systems. However, an effective system requires more than just the radar; plotting and reporting are equally important, and this part of the system was fully developed in Chain Home.
=== Polonnaruwa === On 29 December 2012 a green fireball was observed in Polonnaruwa, Sri Lanka. It disintegrated into fragments that fell to the Earth near the villages of Aralaganwila and Dimbulagala and in a rice field near Dalukkane. Rock samples were submitted to the Medical Research Institute of the Ministry of Health in Colombo. The rocks were sent to the University of Cardiff in Wales for analysis, where Chandra Wickramasinghe's team analyzed them and claimed that they contained extraterrestrial diatoms. From January to March 2013, five papers were published in the fringe Journal of Cosmology outlining various results from teams in the United Kingdom, United States and Germany. However, independent experts in meteoritics stated that the object analyzed by Wickramasinghe's team was of terrestrial origin, a fulgurite created by lightning strikes on Earth. Experts in diatoms complemented the statement, saying that the organisms found in the rock represented a wide range of extant terrestrial taxa, confirming their earthly origin. Wickramasinghe and collaborators responded, using X-ray diffraction, oxygen isotope analysis, and scanning electron microscope observations, in a March 2013 paper asserting that the rocks they found were indeed meteorites, instead of being created by lightning strikes on Earth as stated by scientists from the University of Peradeniya. However, these claims were also criticised for not providing evidence that the rocks were actually meteorites.
== Manufacturing == Paper-based microfluidic devices can be manufactured based on the dimensions, i.e. 2D and 3D. To fabricate 2D paper-based microfluidics, variations of methods, such as wax printing, inkjet printing, photolithography, flexographic printing, plasma treatment, laser treatment, etching (microfabrication), screen printing, digital light processing (DLP) 3-D printer, and wax screening, have been employed. Further lamination of multiple paper microfluidics creates pseudo-3D microfluidics that could provide an additional dimension of the fluidic network and increase the complexity. Each technique aims to create hydrophobic physical barriers on hydrophilic paper that passively transport aqueous solutions. Biological and chemical reagents must then be deposited selectively along the device by either dipping the substrate into a reagent solution or locally spotting a reagent onto the substrate.
Hong Kong is represented in the National People's Congress by 36 deputies chosen through an electoral college and 203 delegates in the National Committee of the Chinese People's Political Consultative Conference appointed by the central government.
Sources: en.wikipedia.org
Bukele created a scholarship program, known as the Dalton Project and funded by his salary, for youth in San Salvador to prevent them from joining gangs. Bukele also created the My New School project to modernize San Salvador's primary schools. In May 2015, he signed an agreement with Panama City mayor José Blandón to establish a sister city relationship between San Salvador and Panama City. In November 2015, Bukele signed an agreement with the Spanish National League of Professional Football to promote sports for San Salvador's youth. In September 2016, Bukele visited Washington, D.C. and met with Mayor Muriel Bowser to discuss the implementation of urban-development projects. Bukele received the keys to the city of Gaithersburg, Maryland, and 11 September was designated the "Day of Mayor Nayib Bukele" ("Día del alcalde Nayib Bukele"). He visited Taipei in February 2017 and met with Taiwanese president Tsai Ing-wen to enhance the sister-city relationship between San Salvador and Taipei. In February 2018, Bukele attended the 32nd International Mayors Conference in Jerusalem and prayed at the Western Wall.
=== September === September 1 Following reports of tensions with US Defense Secretary Pete Hegseth, US Army Secretary Daniel P. Driscoll steps down. The U.S. announces that it struck IRGC targets in Iran after the latter's attacks on commercial shipping in Hormuz and its soldiers, adding that it targeted tankers owned by the National Iranian Oil Company as part of its new "tanker to tanker" policy. Trump states that a most devastating attack is in the works, adding that when it is complete the Iranian government will be in ruins. Trump announces that a major target of those strikes were Iran's efforts to rebuild its radar system. Over $560,000 in cryptocurrency donations for Hamas are seized by the Justice Department. LGBTQ rights in the United States: The Department of Justice files a lawsuit against the Kansas City Public Schools district over its policies that allow transgender students to share their preferred name, gender, and pronouns with school staff. September 2 Birthright citizenship in the United States: American federal judge Deborah Boardman of the U.S. District Court for the District of Maryland blocks an attempt by the Trump administration to implement an executive order aimed at ending birthright citizenship in the United States. Hegseth extends the deployments of approximately 50,000 American soldiers in West Asia, which include warship crews, air defense units, and paratroopers, until 2027. September 3 Chipmaker Nvidia agrees to buy the Hugging Face AI platform in a deal worth $12.9 billion.
The role of the other BDNF receptor, p75, is less clear. While the TrkB receptor interacts with BDNF in a ligand-specific manner, all neurotrophins can interact with the p75 receptor. When the p75 receptor is activated, it leads to activation of NFkB receptor. Thus, neurotrophic signaling may trigger apoptosis rather than survival pathways in cells expressing the p75 receptor in the absence of Trk receptors. Recent studies have revealed a truncated isoform of the TrkB receptor (t-TrkB) may act as a dominant negative to the p75 neurotrophin receptor, inhibiting the activity of p75, and preventing BDNF-mediated cell death.
The mass number of this isotope was not clearly established (possibly 258 or 259) at the time. In 1965, 256Lr was synthesized by Flyorov et al. from 243Am and 18O. Thus IUPAC recognized the nuclear physics teams at Dubna and Berkeley as the co-discoverers of lawrencium.
== Lawsuits == In 2009, Pfizer resolved all but three of 35,000 claims over its withdrawn diabetes drug Rezulin for a total of about $750 million. Pfizer, which acquired rival Wyeth for almost $64 billion, paid about $500 million to settle Rezulin cases consolidated in federal court in New York, according to court filings. The company also paid as much as $250 million to resolve state-court suits. In 2004, it set aside $955 million to end Rezulin cases.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。